Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins

人类 HNF1A 基因的功能获得性变异可预防糖尿病,但同时也会增加肝脏中致动脉粥样硬化脂蛋白的分泌。

阅读:1
作者:Natalie DeForest ,Babu Kavitha ,Siqi Hu ,Roi Isaac ,Lynne Krohn ,Minxian Wang ,Xiaomi Du ,Camila De Arruda Saldanha ,Jenny Gylys ,Edoardo Merli ,Ruben Abagyan ,Laeya Najmi ,Viswanathan Mohan ,Gina M Peloso ,Philip L S M Gordts ,Sven Heinz ,Aimee M Deaton ,Amit V Khera ,Jerrold Olefsky ,Venkatesan Radha ,Amit R Majithia

Abstract

Loss-of-function mutations in hepatocyte nuclear factor 1A (HNF1A) are known to cause rare forms of diabetes and alter hepatic physiology through unclear mechanisms. In the general population, 1:100 individuals carry a rare, protein-coding HNF1A variant, most of unknown functional consequence. To characterize the full allelic series, we performed deep mutational scanning of 11,970 protein-coding HNF1A variants in human hepatocytes and clinical correlation with 553,246 exome-sequenced individuals. Surprisingly, we found that ∼1:5 rare protein-coding HNF1A variants in the general population cause molecular gain of function (GOF), increasing the transcriptional activity of HNF1A by up to 50% and conferring protection from type 2 diabetes (odds ratio [OR] = 0.77, p = 0.007). Increased hepatic expression of HNF1A promoted a pro-atherogenic serum profile mediated in part by enhanced transcription of risk genes including ANGPTL3 and PCSK9. In summary, ∼1:300 individuals carry a GOF variant in HNF1A that protects carriers from diabetes but enhances hepatic secretion of atherogenic lipoproteins. Keywords: ANGPTL3; HNF1A; PCSK9; UK Biobank; atherosclerosis; coronary artery disease; deep mutational scan; diabetes; gain of function; inflammation; saturation mutagenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。